A detailed history of Alliancebernstein L.P. transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 65,590 shares of FULC stock, worth $240,715. This represents 0.0% of its overall portfolio holdings.

Number of Shares
65,590
Previous 222,982 70.59%
Holding current value
$240,715
Previous $1.38 Million 83.07%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.18 - $9.74 $500,506 - $1.53 Million
-157,392 Reduced 70.59%
65,590 $234,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $215,381 - $335,318
36,017 Added 19.26%
222,982 $1.38 Million
Q1 2024

May 14, 2024

SELL
$6.7 - $12.0 $351,703 - $629,916
-52,493 Reduced 21.92%
186,965 $1.76 Million
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $18,825 - $40,611
5,920 Added 2.53%
239,458 $1.62 Million
Q3 2023

Nov 14, 2023

BUY
$3.25 - $6.08 $758,998 - $1.42 Million
233,538 New
233,538 $1.04 Million
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $37,073 - $183,269
13,100 Added 30.61%
55,900 $159,000
Q4 2022

Feb 14, 2023

BUY
$5.01 - $8.35 $26,052 - $43,420
5,200 Added 13.83%
42,800 $311,000
Q3 2022

Nov 15, 2022

BUY
$4.92 - $9.1 $20,172 - $37,310
4,100 Added 12.24%
37,600 $304,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $49,980 - $285,600
11,900 Added 55.09%
33,500 $164,000
Q4 2021

Feb 14, 2022

BUY
$14.0 - $28.44 $70,000 - $142,200
5,000 Added 30.12%
21,600 $382,000
Q2 2021

Jul 30, 2021

BUY
$8.09 - $12.0 $7,281 - $10,800
900 Added 5.73%
16,600 $174,000
Q3 2020

Nov 12, 2020

BUY
$7.22 - $20.7 $5,054 - $14,490
700 Added 4.67%
15,700 $125,000
Q2 2020

Aug 13, 2020

BUY
$9.11 - $22.06 $136,650 - $330,900
15,000 New
15,000 $274,000
Q4 2019

Feb 18, 2020

SELL
$4.46 - $18.14 $2.27 Million - $9.24 Million
-509,369 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$6.64 - $14.89 $3.38 Million - $7.58 Million
509,369 New
509,369 $3.38 Million

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $191M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.